CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
US11142584B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2015 |
| Grant date | Oct 12, 2021 |
| Priority date | — |
| Expiry date | Nov 28, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides CD20-binding proteins that bind to and rapidly internalize in a CD20-mediated fashion from a cell surface location to the interior of the cell. CD20-binding proteins of the invention comprise a CD20 binding region and a Shiga toxin effector region. Certain of the disclosed CD20-binding proteins kill cells that express CD20 on their surface. Further, the presently disclosed CD20-binding proteins can comprise additional exogenous materials, such as, e.g., antigens, and are capable of targeted delivery of these additional exogenous materials into the interior of CD20 expressing cells. These CD20-binding proteins have uses in methods such as, e.g., methods involving the efficient cellular internalization of CD20, targeted killing of CD20 expressing cells, delivering exogenous materials inside CD20 expressing cells, detecting CD20 expressing cells, and treating a variety of conditions involving CD20 expressing cells including cancers, tumors, growth abnormalities, and immune disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.